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Abstract
Severe pruritus is a rare complication of cancer. Although many patients  with or without cancer suffer of
mild pruritus due to generic causes like dry skin, candida infections and local inflammation, very few suffer
severe pruritus. Similarly to the concept of "cancer pain", there is nothing like "pruritus of cancer", no common
mechanism and no common treatment. Thorough analysis and deduction as well as laboratory  and image
investigations are necessary to unravel possible cause and help choose appropriate treatment. Many treat-
ments, appear to be effective against pruritus judging from the number of case reports, but render ineffec-
tive in controlled clinical trials.
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Introduction
Severe pruritus is a rare complication of cancer
[1]. Although many patients with or without can-
cer suffer of mild pruritus due to generic causes
like dry skin, candida infections and local inflam-
mation, very few suffer severe pruritus [2]. Similar-
ly to the concept of “cancer pain”, there is nothing
like “pruritus of cancer”, no common mechanism
and no common treatment. Thorough analysis and
deduction as well as laboratory and image investi-
gations are necessary to unravel possible cause and
help choose appropriate treatment [3]. As the
knowledge of “pruritus in cancer” conditions is lim-
ited, typical treatment plan would be organised in
three or more steps which should be tried after
each other. Sometimes combination of several
modalities is necessary to satisfactorily control pru-
ritus [4].
Mechanisms of pruritus in cancer
Most of the cancer patients experiencing severe
itch can be classified as patients with cholestasis.
This cholestasis is usually due to extra- or intrahe-
patic bile retention due to bile duct and pancreas
tumours or, more often, intrahepatic metastases of
other distant tumours. Itch of cholestasis may also
result from an ill understood paraneoplastic phe-
nomenon and in this kind of patients drainage of
the bile by insertion of bile duct stent will relieve
jaundice, but not pruritus. Cholestasis may also re-
sult from hepatotoxic drugs. As in advanced dis-
ease, patients may become more vulnerable for this
mechanism as in general their resilience decreases.
Simple discontinuation of the suspected drugs, one
by one, may lead to resolution of the itch.
There may be some patients who will suffer of
paraneoplastic itch, unrelated to cholestasis. In
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these patients it is typical that suppression of the
tumour growth will suppress itch, but recurrence
of this symptoms may herald recurrence of the
tumour. This type of itch frequently preceded di-
agnosis of cancer by months and sometimes by
years [5]. In this context lymphomas are notori-
ous [6].
Finally, many patients will experience localized
itch due to neuropathy. This neuropathy may result
from localized tumour growth and damage to the
nerves [7–9]. Neuropathy may result from neural
shingles infection [10, 11] or from damage to the
nerves by the treatment of cancer. In this latter cat-
egory one can find all kind of neurotoxic effects of
chemotherapy [12–14] and radiotherapy [15]. New
therapies, like biologic response modifiers may also
be toxic and cause persistent itch [16–18].
The specific mechanisms and available treat-
ments will be now discussed in more details.
Cholestasis and cholestyramine
Bile acids are metabolites of cholesterol and their
accumulation was thought for a long time as patog-
nomonic for pruritus in liver diseases [19]. Injection
of bile acids intracutaneously causes itch [20, 21].
However, patients with cholestasis advance into
hepatic failure stop itching despite accumulation of
bile acids [22]. This happens when androgens are
used to treat itch: itch is decreasing despite the
surge of bile acids in blood [22]. Removal of bile
acids from the plasma by ion exchange resin
cholestyramine used to treat hypercholesterolaemia
helps only for some time. Although this therapy is
known for many years, rigorous clinical trials are
still missing. Above all cholestyramine may adsorb
many other things, also potential pruritogens, so
this drug is not selective at all. Adsorption of vita-
min K may cause serious bleeding in patients with
cancer. Cholestyramine helps also in cases of pruri-
tus due to policythaemia vera which has nothing
to do with cholestasis and bile acids [23]. In the
context of cancer and cholestasis due to obstruc-
tion of external bile duct it is important to state
that cholestyramine will not help in case of jaun-
dice when the bile is not pouring into the duode-
num. In this context it is interesting that nasobil-
iary drainage was found useful in several pruritic
patients [24, 25].
Interesting aspect of cholestyramine is that it is
associated with release of cholecystokinin [26] and
endogenous opioids [27]. In this way cholestyramine
may influence opioidergic tone. And this is the clue
to understand pruritus of cholestasis.
Cholestasis and opioids
Cholestatic rodents subjected to resection of their
bile ducts present with a naloxone reversible anal-
gesia and pruritus [28–30]. Increase of activity of
mu-specific opioids increases itch transmission and
induces analgesia while treatment with kappa-opi-
oid agonists U50488H [31, 32] reduces itch. Also
well known is antipruritic effect of opioids antago-
nists like naloxone and naltrexone [33, 34]. In non-
malignant diseases naloxone and naltrexone is the
treatment of choice of pruritus [34–37]. However,
in malignant disease there is a need of a different
approach. Rapid reversal of opioids analgesia, which
we believe is present in many patients with cholesta-
sis may on one side control itch but may also induce
pain. Juby et al. proposed in 1994 treatment with
buprenorphine [38]. This opioids drug has a high
affinity to the opioids receptors and my make them
unavailable to the pruritogenic endogenous opio-
ids [35]. This approach had been tried in a clinical
trial in time when only high dose sublingual prepa-
rations of buprenorphine were available [38]. Not
surprising that this drug was found very toxic and
the trial was prematurely discontinued. Several pa-
tients responded to this therapy with decrease of
itch. Recently buprenorphine became available in
patches and made titration to effect, avoiding tox-
icity possible. Single successful cases of antipruritic
activity of this drug were reported [39–41].
Pruritus and serotoninergic system
We do not know exactly how serotoninergic sys-
tem is connected to the opioids. However, some
patients with cholestatic pruritus, but also with a
plethora of other conditions may respond to ad-
ministration of SSRIs. It appears that paroxetine and
probably also sertraline are especially effective in
the treatment of paraneoplastic itch. Administra-
tion of paroxetine in patient with cholestasis may
evoke reaction that clinically is indistinguishable to
opioids abstinence syndrome evoked by naloxone
(Zylicz — unpublished). Also, after failure of naltr-
exone to relieve itch, paroxetine is usually ineffec-
tive too (Zylicz — unpublished). Use of SSRIs for
relieve of itch was observed empirically [42]. Later
several clinical trials were performed, all of them
confirming the original observation [43–46]. Nau-
sea and vomiting observed in patients treated with
paroxetine [43] can best be avoided by careful in-
crements of the dose [44]. In this context it is inter-
esting to note that some patients with cholestasis
will present with a codeine resistant dry cough [47,
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48]. This cough responds very well to administra-
tion of any type of SSRIs [48]. Clinical trials are on
their way to confirm this interesting observation.
Several years ago a lot of attention was paid to
the use of ondansetron in the treatment of itch,
especially itch of cholestasis [49–51]. However, con-
trolled trial did not confirm this effect [52]. In this
context it is interesting to state that ondansetron
may have a potential to control fatigue accompa-
nying cholestasis [53, 54]. Author uses from time
to time subcutaneus tropisetron to relieve itch in a
patient who can not take medicines orally, with
remarkable effect. The difference between poor
response in clinical trial and reported cases can be
explained by variable bioavailability of ondansetron.
The HT3 receptor antagonists appeared to be anti-
pruritic only in opioids induced itch [55, 56].
Among other drugs interacting with serotonin-
ergic system mirtazapine warrants further investi-
gations [57, 58].
Rifampicin
Rifampicin is an antibiotic but it also induces
liver enzymes. Although the antipruritic mechanism
of rifampicin is still unknown, many people think
that inducing the metabolic mashine of the liver
will speed the metabolism of an unknown
pruritogen(s) in the liver [59]. In a double blind
trial rifampicin appeared to be effective as an anti-
pruritic agent in the dose of 300–450 mg per day
[60]. Although rifampicin is present in almost all
guidelines to treat itch it must be pointed out that
this drug is hepatotoxic and close monitoring of
the liver panel is advisable. Treatment with the
low dose, 75 mg is advisable initially and the dose
can be gradualny increased. Because of this rifampi-
cin can not be given chronically, something which
is needed by many patients suffering from this
condition.
Treatment of neuropathic itch
Neuropathic itch can be best treated in the same
way as neuropathic pain. Gabapentin is effective
against some form of this itch [61–63]. However,
this therapy appears to be effective also in pruritus
unrelated to neuropathy [64–67]. Antidepressants,
including SSRIs may be tried, but there is an insuffi-
cient body of evidence to advocate this. Epidural
clonidine may be tried too as it was effective in
several cases of pruritus due to herpes zoster [68].
Other options are discussed in the recent article by
Yosipovitch [69].
Opioid induced pruritus
Opioid induced pruritus is rare after oral or
parenterally administration of opioids. It is so rare
that its presence may indicate reaction to other than
opioids component of the medication. Itch follow-
ing systemic opioids administration responds well
to antihistamines which suggest an allergic reac-
tion. It is different in case of opioids administered
spinally. The prevalence of itch in spinal opioids
administration is very high [70]. Especially in wom-
en before Caesarian section, spinal opioids induce
always itch. Bupivacaine added to spinal opioids
nearly always ameliorates itch [71–73]. Interesting-
ly diclofenac and other NSAIDs are able to reduce
itch due to spinal opioids suggesting that prostag-
landines but not histamine are involved in this mech-
anism [74, 75].
Conclusion
Severe itch can be very annoying to the patients
with malignancies. Although the direct effect of tu-
mour growth on itch is still under investigation,
cancer patients suffer most often of itch due to
cholestasis. This condition is best treated with bile
drainage but sometimes this is impossible due to
advanced disease. Other measures, among which
buprenorphine patches should be investigated. Also
the use of SSRIs is promising in this context. Many
treatments, like ondansetron, appear to be effec-
tive against pruritus judging from the number of
case reports, but render ineffective in controlled clin-
ical trials.
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